<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604238</url>
  </required_header>
  <id_info>
    <org_study_id>Azienda USL1 Massa e Carrara</org_study_id>
    <nct_id>NCT02604238</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism</brief_title>
  <acronym>MONALYSE</acronym>
  <official_title>Efficacy and Safety of Thrombolytic Therapy With Half Dose Alteplase, Added to Standard Anticoagulation Therapy With Heparine, in Patients With Moderate Pulmonary Embolism: a Prospective, Randomized, Open Label,Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda U.S.L. 1 di Massa e Carrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda U.S.L. 1 di Massa e Carrara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to evaluate whether mid dose (safe dose) of Alteplase in&#xD;
      addition to standard treatment with heparin (LMWH) in patients with pulmonary embolism (PE)&#xD;
      at intermediate risk, it is effective to reduce:&#xD;
&#xD;
        -  right ventricular dysfunction&#xD;
&#xD;
        -  pulmonary hypertension 24 hours and 7 days after the treatment&#xD;
&#xD;
        -  PE recurrence to 7days and 30 days after the treatment without increasing the incidence&#xD;
           of bleeding intra-extracranial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The guidelines of the European Society of Cardiology (ESC2014) confirm the indication for&#xD;
      pharmacological revascularization with thrombolysis only to cases of pulmonary embolism at&#xD;
      high risk and thus hemodynamically unstable (class of recommendation I, level of evidence B),&#xD;
      reserving the surgical or interventional procedures to cases where thrombolysis has failed or&#xD;
      is contraindicated, while it remains controversial the role of thrombolysis in patients with&#xD;
      pulmonary embolism at intermediate risk; the current state, in EP intermediate risk, the&#xD;
      standard treatment involves the administration of low molecular weight heparin (LMWH), or&#xD;
      fondaparinux (for 5-10 days followed by anticoagulation therapy with vitamin K antagonists)&#xD;
      or alternatively the new anticoagulants oral (NAO). Although the results of the study PEITHO,&#xD;
      recently published, confirm the indication for thrombolytic therapy for primary reperfusion&#xD;
      in patients with embolism pulmonary high risk and provide element of reflection about the&#xD;
      incidence of intracranial hemorrhage major, recent studies suggest that the thrombolysis with&#xD;
      tPA to reduced dose (about half the dose that used in standard thrombolysis) in addition to&#xD;
      anticoagulants (low molecular weight heparin) may reduce pulmonary hypertension (systolic&#xD;
      artery pulmonary pressure&gt; 40 mmHg) and the incidence of recurrent PE. In this protocol,&#xD;
      based on the study MOPETT and pharmacokinetic data available, it is used a &quot;safe dose&quot; (safe&#xD;
      dose reduced) of alteplase which provides a intravenous (iv) bolus loading dose of 10 mg in 1&#xD;
      min, followed by intravenous infusion 40 mg within two hours (for patients weighing &lt;50 kg&#xD;
      loading dose iv bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg within two hours).&#xD;
&#xD;
      After treatment with alteplase, the heparin therapy will be resumed when aPTT values are less&#xD;
      than twice the upper limit of normal; the infusion will be adjusted to maintain aPTT between&#xD;
      50-70 seconds (1.5 to 2.5 times the reference value), and for safety reasons are excluded&#xD;
      patients&gt; 65 -70 years (increased risk of bleeding complications related age and&#xD;
      comorbidities).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary hypertension reduction (systolic pulmonary pressure greater or equal to 30 mm Hg)</measure>
    <time_frame>24 hour</time_frame>
    <description>Pulmonary hypertension reduction documented on echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of recurrent pulmonary embolism fatal or non fatal</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of recurrent pulmonary embolism fatal or non fatal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hemodynamic shock</measure>
    <time_frame>24 hour and 30 days</time_frame>
    <description>Incidence of hemodynamic shock [defined as: need for cardiopulmonary resuscitation, or SBP &lt;90 mmHg for a period ≥15 min or reduction SBP ≥40 mm Hg for SBP ≥15 min, with evidence of systemic hypoperfusion (cold extremities, diuresis &lt;30 mL / h, mental confusion), or need for infusion of amines to maintain adequate organ perfusion and SBP&gt; 90 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospital death from all causes</measure>
    <time_frame>30days</time_frame>
    <description>Incidence of hospital death from all causes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bleeding extracranial minor and major</measure>
    <time_frame>24 hour and 30 days</time_frame>
    <description>Bleeding extracranial minor and major</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered a &quot;safe dose&quot; of Alteplase. All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin in addition it is administered a &quot;safe dose&quot; of Alteplase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin. It not added any treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>Enoxaparin (1mg) 100UI aXa/kg/sc [LMWH], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing &lt;50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>tPA-tissue Plasminigen Activator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. pulmonary embolism at intermediate risk as defined by the Guidelines ESC2014[&#xD;
             documented pulmonary CT angiography]&#xD;
&#xD;
          2. pulmonary hypertension (systolic pulmonary pressure greater or equal to 40 mm Hg)&#xD;
             [documented echocardiogram presence of thrombotic material in the right-sided]&#xD;
&#xD;
          3. disfunction Ventricular right confirmed by echocardiogram or TC chest:&#xD;
&#xD;
               -  dilation of the right sections (&gt; 30 mm in parasternal or relationship right&#xD;
                  ventricle/left ventricle &gt; 1)&#xD;
&#xD;
               -  paradoxical movement of the interventricular septum&#xD;
&#xD;
               -  TAPSE reduced (Tricuspid Annular Plane Systolic Excursion)&#xD;
&#xD;
               -  tricuspid regurgitation with gradient VD/AD&gt; 30 mmHg, in the absence of right&#xD;
                  ventricular hypertrophy, McConnell sign (apical segment of the free wall of the&#xD;
                  right ventricle normalKinetic or hyperkinetic than a hypokinesia or akinesia of&#xD;
                  the remaining parts of the right ventricular wall),&#xD;
&#xD;
          4. myocardial damage confirmed with:&#xD;
&#xD;
               -  Troponin I or T positive&#xD;
&#xD;
               -  higt value of the biomarkers of myocardial damage : BNP or NTproBNP&#xD;
&#xD;
          5. informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. age &lt;18 years and&gt; 65 years&#xD;
&#xD;
          2. HASBLED score ≥ 3 (23)&#xD;
&#xD;
          3. intracranial tumors&#xD;
&#xD;
          4. ischemic stroke within 2 months&#xD;
&#xD;
          5. surgery neurological within 1 month and surgery within 10 days&#xD;
&#xD;
          6. trauma within 15 days&#xD;
&#xD;
          7. hypotension to hospitalization (systemic blood pressure &lt;90 mmHg)&#xD;
&#xD;
          8. uncontrolled hypertension (SBP&gt; 180mmHg and PAD&gt; 110mmHg)&#xD;
&#xD;
          9. clotting disorders&#xD;
&#xD;
         10. thrombocytopenia (&lt;100.000)&#xD;
&#xD;
         11. platelet counts below 100 × 109 /L severe thrombocytopenia (platelet count &lt;50.000 ptl&#xD;
             / mm3)&#xD;
&#xD;
         12. liver failure&#xD;
&#xD;
         13. kidney failure&#xD;
&#xD;
         14. gastrointestinal bleeding within 10 days&#xD;
&#xD;
         15. pregnancy or childbirth within 30 days&#xD;
&#xD;
         16. contraindications to the use of thrombolytics&#xD;
&#xD;
         17. contraindications to the use of low molecular weight heparin (enoxaparin)&#xD;
&#xD;
         18. anticoagulation therapy started more than 8 hours&#xD;
&#xD;
         19. COPD&#xD;
&#xD;
         20. endocarditis&#xD;
&#xD;
         21. severe obesity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Conti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda USL1 di Massa e Carrara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberto Conti, MD</last_name>
    <phone>3601095575</phone>
    <email>aaaconti@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lorella Magnani, PharmD</last_name>
    <phone>0585498087</phone>
    <email>lorella.magnani@usl1.toscana.it</email>
  </overall_contact_backup>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Embolism at intermediate risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

